logo phoenix Scientific Publications, Posters & Presentations

Scientific Publications, Posters & Presentations |Patents & Intellectual Property

Scientific Publications, Posters & Presentations

Publications
Publications that have resulted from Ardea Biosciences’ proprietary research programs or through research collaborations with other biotechnology or pharmaceutical companies will be posted below once available. The links for the articles go to subscription-based sites and may require a fee to view the article.

Presentations

  48th Annual ICAAC/IDSA 46th Annual Meeting
RDEA806, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment Naïve HIV Patients RDEA806, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment Naïve HIV Patients
  2008 ACR/ARHP Annual Scientific Meeting
MEK Inhibitor RDEA119 Suppresses Inflammatory Cytokine Production Induced by Monosodium Urate Crystals MEK Inhibitor RDEA119 Suppresses Inflammatory Cytokine Production Induced by Monosodium Urate Crystals
  XVII International AIDS Conference
IAS Presentation Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients
  Digestive Disease Week 2008
RDEA119, A Potent and Highly RDEA119, A Potent and Highly Selective MEK Inhibitor Ameliorates Murine Colitis

 

Posters

RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in Hyperuricemic Gout Patients RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in Hyperuricemic Gout Patients
Evaluation of Drug-Drug Interaction Potential Between RDEA594, Allopurinol and Febuxostat in Preclinical Species

Evaluation of Drug-Drug Interaction Potential Between RDEA594, Allopurinol and Febuxostat in Preclinical Species

Safety, Pharmacokinetics, and Serum Uric Acid Lowering Effect of RDEA594, A Novel Uricosuric Agent, In Healthy Volunteers Safety, Pharmacokinetics, and Serum Uric Acid Lowering Effect of RDEA594, A Novel, Uricosuric Agent, In Healthy Volunteers
RDEA594: A Potent URAT1 Inhibitor Without Affecting Other Important Renal Transporters, OAT1 and OAT3 RDEA594: A Potent URAT1 Inhibitor Without Affecting Other Important Renal Transporters, OAT1 and OAT3
SELECTIVE MEK1/2 INHIBITORS RDEA436 AND RDEA119 Selective MEK1/2 Inhibitors RDEA436 and RDEA119 Exhibit Anti-Inflammatory Efficacy in Mono and Combination Therapy with Methotrexate in Pristane-Induced Arthritis in Rats
The Selective MEK Inhibitor RDEA119: Synergy with Multiple Classes of Anti-Cancer Agents The Selective MEK Inhibitor RDEA119: Synergy with Multiple Classes of Anti-Cancer Agents
RDEA427 CROI 2009 Poster 2-3-09 In Vitro Resistance Selection Study and Favorable PK Properties of RDEA427, a New NNRTI
RDEA594, a Potential Uric Acid Lowering Agent through Inhibition of Uric Acid Reuptake, Shows Better Pharmacokinetics than its Prodrug RDEA806 RDEA594, a Potential Uric Acid Lowering Agent through Inhibition of Uric Acid Reuptake, Shows Better Pharmacokinetics than its Prodrug RDEA806
The Effect of MEK Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a Phase 1 Clinical Trial The Effect of MEK Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a Phase 1 Clinical Trial
Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTI’s Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTI’s
RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer
RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis in Mice RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis in Mice
Design and Synthesis of RDEA119 a Potent and Orally Bioavailable MEK Inhibitor Design and Synthesis of RDEA119 a Potent and Orally Bioavailable MEK Inhibitor
Biosynthesis of Oxidative and Conjugated Metabolites of VRX-480773 and

Biosynthesis of Oxidative and Conjugated Metabolites of VRX-480773 and Identification of their Structures by LC-MS/MS and NMR

RDEA806 Safety and Uric Acid Lowering Safety and Uric Acid Lowering Effect in Humans Following Multiple Doses of RDEA806, a Novel Prodrug for the Potential Treatment of Hyperuricemia
Mode of Action of RDEA594 Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans Following Multiple Doses of its Pro-drug, RDEA806
RDEA119, A Selective MEK RDEA119, A Selective MEK 1/2 Inhibitor Ameliorates Experimental Arthritis
RDEA436, a Novel MEK Inhibitor with Favorable  Pharmacokinetic Properties RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties
RDEA119, A Potent and Highly Specific MEK Inhibitor RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies
Novel NNRTI A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses
RDEA 427 and RDEA 640 Novel NNRTIs RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses
RDEA 806 IQ Assessment Potent NNRTI An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins
RDEA119 RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer
Discovery of RDEA806 The Discovery of RDEA806, a Potent New HIV NNRTI in Phase 1 Clinical Trials
RDEA806 a Potent NNRTI RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance
RDEA806 Phase I Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers
RDEA806 Drug Drug Interactions RDEA806, A Potent Non-Nucleoside Reverse Transcriptase Inhibitor
with Less Potential for Drug-Drug Interactions
www.ardeabio.com © 2007 | Privacy Policy | Legal Policy | Site Map